Endomedix
Medical Devices, 1 University Ave, Montclair, New Jersey, 07043, United States, 1-10 Employees
Phone Number: 18*********
Who is ENDOMEDIX
Endomedix is a development stage MedTech firm that has developed a platform technology (PLEXimineTM) based on novel polysaccharide chemistry. PLEXimine forms devices in situ that are stru...
Read More
-
Headquarters: 1 University Ave, Montclair, New Jersey, 07043, United States
-
Date Founded: 2014
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 3841
|
NAICS Code: 561110 |
Show More
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Endomedix
Answer: Endomedix's headquarters are located at 1 University Ave, Montclair, New Jersey, 07043, United States
Answer: Endomedix's phone number is 18*********
Answer: Endomedix's official website is https://endomedix.com
Answer: Endomedix's revenue is $1 Million to $5 Million
Answer: Endomedix's SIC: 3841
Answer: Endomedix's NAICS: 561110
Answer: Endomedix has 1-10 employees
Answer: Endomedix is in Medical Devices
Answer: Endomedix contact info: Phone number: 18********* Website: https://endomedix.com
Answer: Endomedix is a development stage MedTech firm that has developed a platform technology (PLEXimineTM) based on novel polysaccharide chemistry. PLEXimine forms devices in situ that are structured and dynamic 3D networks. This technology is versatile and can produce an array of different properties for use in the development of a series of separate product categories. Endomedix has been awarded 7 NIH SBIR & 1 NYS grants, and has obtained 9 issued patents based for this technology. The first device using this technology will be PlexiClotTM Absorbable Hemostat for brain & spinal surgeries, an underserved $1.7B niche. PlexiClot addresses major unmet needs in these high value surgeries with a unique technology that cannot be equaled by existing technologies. Additionally, the Company has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Materiel Development Command (USAMMC) for the development of a treatment system for ocular projectile battlefield trauma using PLEXimine technology. In addition to grants, the Company has raised $3.3 M in private investment.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month